Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Edward A. Stadtmauer
Mast cells may promote myeloma engraftment in the NSG-hIL6 patient derived xenograft model
Abstract Multiple myeloma remains a fatal, incurable disease. Most therapies are targeted to the cancer cell or T cell engagement. Little is known about the supporting myeloma microenvironment and its contribution to tumor fitness. Here, we expand upon the observation of human mast cells in the NSG-hIL6 myeloma patient derived xenograft mouse model to correlate mast cells to decreased engraftment time and increased overall myeloma engraftment. Mast cells may also correlate to worsened bone disease.
Progressive Multifocal Leukoencephalopathy in Multiple Myeloma
Abstract Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal demyelinating disease of the central nervous system caused by reactivation of the JC virus in the context of immune suppression such as HIV, malignancy, and certain immunomodulatory medications. PML has been reported only rarely in multiple myeloma patients, and its presenting features and natural history in this population are not well known.
Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM
Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania - Episode 10 Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.
Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability
Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania - Episode 7 Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability Before closing out their review of treatment for transplant-eligible multiple myeloma, panelists consider how they might adjust therapy to optimize tolerability or efficacy.
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania - Episode 8 Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma Expert oncologists focus on a final patient case of transplant-ineligible newly diagnosed multiple myeloma and reflect on the treatment armamentarium in this setting.
Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM
Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania - Episode 6 Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM Shared insight on the optimal selection of induction therapy for patients with high-risk transplant-eligible newly diagnosed multiple myeloma.
Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania - Episode 4 Consolidation and Maintenance Therapy in Transplant-Eligible NDMM A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.
Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania - Episode 1 Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma Expert panelists review the case of transplant-eligible newly diagnosed multiple myeloma and consider optimal selection of induction therapy.
Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy
In an editorial accompanying the final results of the TOURMALINE-MM1 study,1 Drs D'Souza and Lonial2 question whether overall survival (OS) is “still the gold standard for demonstrating the value of a novel agent in phase III trials early in the disease course given the current treatment landscape.” The authors raise concern that the continuous treatment model for multiple myeloma, in which patients are expected to receive multiple lines of therapy over the course of their illness, “confounds...
First and Second-Line Treatment Protocols for Multiple Myeloma
Published on August 24, 2021 Multiple Myeloma Experts Explain the Treatment Classes Listen in as Alfred Garfall, MD, and Edward Stadtmauer, MD, from Penn Medicine talk to host Cindy Chmielewski about the different classes of treatments that are available to individuals with multiple myeloma. This includes an overview of second-line treatments, therapies suitable for patients who have relapsed, and a discussion of whether an intensive first line of treatment is effective for long-term results.
CRISPR-engineered T cells in patients with refractory cancer
CRISPR takes first steps in humans CRISPR-Cas9 is a revolutionary gene-editing technology that offers the potential to treat diseases such as cancer, but the effects of CRISPR in patients are currently unknown. Stadtmauer et al. report a phase 1 clinical trial to assess the safety and feasibility of CRISPR-Cas9 gene editing in three patients with advanced cancer (see the Perspective by Hamilton and Doudna).
CRISPR-engineered T cells in patients with refractory cancer
Abstract CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells to fight cancer. We report a first-in-human phase I clinical trial to test the safety and feasibility of multiplex CRISPR-Cas9 editing to engineer T cells in three patients with refractory cancer.
CRISPR-engineered T cells in patients with refractory cancer
By Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis, Adam D. Cohen, Kristy L. Weber, Eric Lancaster, Patricia A. Mangan, Irina Kulikovskaya, Minnal Gupta, Fang Chen, Lifeng Tian, Vanessa E. Gonzalez, Jun Xu, In-young Jung, J. Joseph Melenhorst, Gabriela Plesa, Joanne Shea, Tina Matlawski, Amanda Cervini, Avery L. Gaymon, Stephanie Desjardins, Anne Lamontagne, January Salas-Mckee, Andrew Fesnak, Donald L. Siegel, Bruce L. Levine, Julie K. Jadlowsky, Regina M.
CRISPR-edited T cells appear safe for patients with cancer
ORLANDO — Immune cells genetically edited with CRISPR/Cas9 technology and infused back into patients with multiple myeloma and sarcoma appeared to be safe and represent a feasible therapeutic approach, according to results of a prospective phase 1 study presented at ASH Annual Meeting and Exposition. “CRISPR technology allows us to edit genes in cells. The question is how to best use that technology to treat cancer,” Edward A.
CRISPR-edited T cells appear safe for patients with cancer
December 07, 2019 4 min read Save ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Clinical MedicineClinical trialsOncology Free access | 10.1172/JCI126397 Adam D. Cohen,1 Alfred L. Garfall,1 Edward A. Stadtmauer,1 J. Joseph Melenhorst,2 Simon F. Lacey,2 Eric Lancaster,3 Dan T. Vogl,1 Brendan M. Weiss,1 Karen Dengel,2 Annemarie Nelson,2 Gabriela Plesa,2 Fang Chen,2 Megan M. Davis,2 Wei-Ting Hwang,4 Regina M. Young,2 Jennifer L. Brogdon,5 Randi Isaacs,5 Iulian Pruteanu-Malinici,5 Don L. Siegel,2,6 Bruce L. Levine,2,6 Carl H. June,2,6 and Michael C.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Edward A.
Contact Edward A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack